J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
at The Street - Mon Dec 22, 7:23AM CST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
VRX: 140.33 (-0.22), BMRN: 88.18 (+0.89), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), ILMN: 186.22 (+2.72), BMY: 59.15 (-0.01)
Top Pharmaceutical Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 20, 8:05AM CST
Source: Flickr user stockmonkeys.com. It has been tough lately for big pharmaceutical stocks to overcome the headwinds tied to patent expiration on some of the world's best-selling medicines. As a result, pharmaceutical stocks haven't been as...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), JAZZ: 165.33 (+1.83)
Top 5 IBD 50 Stalwarts, Newcomers In Turbulent Year
at Investor's Business Daily - Sat Dec 20, 7:02AM CST
The IBD 50 list of top-rated stocks identifies new market leaders as well as veterans that continue to outperform the market. A comparison of stocks on the current IBD 50 vs. the list from a year ago pinpoints four stocks -- Facebook, Noah Holdings,...
NOAH: 20.44 (-1.00), SAVE: 75.68 (+1.52), FB: 80.77 (+0.16), JAZZ: 165.33 (+1.83), GOOG: 528.77 (-1.82), BITA: 72.57 (+0.36), UAL: 64.93 (+2.45)
Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze(R) (asparaginase Erwinia chrysanthemi)
PR Newswire Europe - Fri Dec 19, 6:05PM CST
-- Expanded U.S. Labeling Offers an Alternative Method to Administer Erwinaze to Patients with ALL
JAZZ: 165.33 (+1.83)
Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze® (asparaginase Erwinia chrysanthemi)
PR Newswire - Fri Dec 19, 6:05PM CST
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase1.
JAZZ: 165.33 (+1.83)
Flamel progresses on single dose narcolepsy treatment
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 12:13PM CST
FLML: 17.01 (-0.98), JAZZ: 165.33 (+1.83)
How To Invest: Taking Stock Tips Can Mean Disaster
at Investor's Business Daily - Mon Dec 15, 4:58PM CST
To be a successful investor, it's very important to make decisions based on your own research and analysis. You have to stand on your own two feet. One recipe for disaster is to accept stock tips, be they from TV commentators or friends. Even if the...
JAZZ: 165.33 (+1.83)
Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 4:50PM CST
Jazz Pharmaceuticals (JAZZ) has started the rolling submission of a NDA for defibrotide.
BIIB: 340.89 (+5.13), JAZZ: 165.33 (+1.83), AMGN: 160.67 (+3.15), AFFX: 9.80 (+0.05)
Stocks Close Near Session Lows And Down For The Week
at Investor's Business Daily - Fri Dec 12, 3:33PM CST
Stocks closed lower Friday and near their lows for the day with the S&P 500 and the Dow Jones industrial average having their first down week in the past eight. For the Nasdaq, it was the second straight down week. In the stock market today, the...
ZUMZ: 37.53 (-0.31), CALM: 42.45 (-1.73), JAZZ: 165.33 (+1.83), CAR: 64.23 (-0.25), URI: 104.84 (+0.16)
Jazz kicks off Fast Track review process for VOD med
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 12:28PM CST
JAZZ: 165.33 (+1.83)
Stocks Down In Afternoon; Caterpillar, Joy Global Hit
at Investor's Business Daily - Fri Dec 12, 12:28PM CST
Stocks remained in negative territory early Friday afternoon as weak Chinese manufacturing data and falling oil prices fanned concerns of a global economic slowdown. The Dow Jones industrial average lost 1%, the S&P 500 fell 0.6% and the Nasdaq...
CNC: 105.96 (+1.03), JOY: 48.23 (+0.31), JAZZ: 165.33 (+1.83), CAT: 93.72 (+0.22), URI: 104.84 (+0.16)
Insider Trading Alert - JAZZ, ARE And SCLN Traded By Insiders
at The Street - Fri Dec 12, 10:30AM CST
Stocks with insider trader activity include JAZZ, ARE and SCLN
ARE: 89.23 (-0.23), JAZZ: 165.33 (+1.83), SCLN: 8.64 (+0.16)
Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease
PR Newswire Europe - Thu Dec 11, 3:05PM CST
-- Expects to complete submission in the first half of 2015
JAZZ: 165.33 (+1.83)
JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:39PM CST
Jazz Pharmaceuticals (JAZZ) shares slipped after announcing that JZP-386 was not administered in the first phase I study due to a technical dosing issue.
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), JAZZ: 165.33 (+1.83), CNCE: 11.76 (+0.11)
Look for Shares of Jazz Pharmaceuticals to Potentially Rebound after Yesterday's 2.64% Sell Off
Comtex SmarTrend(R) - Tue Dec 09, 4:21PM CST
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $172.65 to a high of $179.87. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $177.10 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 165.33 (+1.83)
Stock Market Today: Wall Street Drops; Conn's Down 40%
at Investor's Business Daily - Tue Dec 09, 10:55AM CST
Stocks were sharply lower in heavy volume at midday Tuesday, as falling oil prices prompted fears of a global economic slowdown. The Dow Jones industrial average was down 0.9%, the S&P 500 lost 0.8% and the Nasdaq slipped 0.6%. Volume was running...
CAVM: 62.46 (+0.43), ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), JAZZ: 165.33 (+1.83), CONN: 18.23 (+1.23)
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Business Wire - Tue Dec 09, 7:30AM CST
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.
JAZZ: 165.33 (+1.83), CNCE: 11.76 (+0.11)
Top Global Stocks: Jazz, Actavis In IBD's World List
at Investor's Business Daily - Mon Dec 08, 5:39PM CST
Three top-ranked drugmakers are among IBD's 10 leading global growth stocks. One is in buying range. Jazz Pharmaceuticals (JAZZ) appears to have gained some traction after a disappointing breakout Nov. 5, when the stock cleared its buy point only to...
MNK: 97.84 (-0.29), JNJ: 104.59 (+0.31), ACT: 254.20 (-1.68), COV: 103.35 (+0.57), JAZZ: 165.33 (+1.83)
Stocks Sink In Late Trading: Tesla, McDonald's Dive
at Investor's Business Daily - Mon Dec 08, 2:06PM CST
Stocks stretched losses heading into the final hour of trading Monday. In the stock market today the Nasdaq fell 0.9%, the S&P 500 dropped 0.7%, and the Dow trimmed 0.6%. Volume was tracking higher across the board compared with Friday's levels. From...
TSLA: 222.26 (+1.29), AKRX: 36.47 (+0.43), UTX: 116.91 (-0.30), JAZZ: 165.33 (+1.83), MCD: 93.83 (-0.39), CELG: 109.60 (+3.48)